Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disorder with unclear pathogenesis. The prevalence of AS in the general population is estimated at 0.5%, and its prominent features include sacroiliitis, spondylitis, asymmetric peripheral arthritis, enthesitis and an association with the histocompatibility allele HLA-B27. AS disease activity can be appreciated by clinical and laboratory measures, such as the severity of the inflammatory back pain, presence of synovial or entheseal inflammation, acute uveitis, constitutional symptoms and elevated indices of inflammation in the blood such as erythrocyte sedimentation rate and/ or serum levels of C-reactive protein (CRP). The pathologic progression of AS is measured by new bone formation, appearance of syndesmophytes at vertebral body margins and, eventually, ankylosis of the sacroiliac joints and vertebral column. The presence of inflammation at the areas of subsequent osseous proliferation is considered to be a necessary trigger; but, on the other hand, the rate of new bone formation in AS does not seem to be a simple function of the inflammatory activity of the disease, and the precise mechanisms of the progressive ankylosis are unknown. It is also well appreciated that the rate and course of new bone formation can be individually determined, with some AS patients having radiographic ankylosis already upon first clinical presentation, while others do not develop ankylosis even after longstanding disease. The factors influencing this significant variability in both rate and magnitude of new bone formation in individuals with AS have not been elaborated. The aim of this review was to summarize the current knowledge regarding both clinical significance and pathogenesis of bone formation in AS.
Materials and methods
A literature search of the PUBMED database using the crossover of keywords 'bone formation' and 'ankylosing spondylitis' was conducted, with 227 papers listed. These manuscripts, as well as other articles published in the medical literature and chapters in textbooks related to the discussed topic, were critically reviewed and relevant data were selected, collated and organized for the purpose of this article.
Results

Radiographic features of bone formation in AS
Bone formation is a characteristic feature of AS, which, if properly recognized, has an important role in diagnosing, classifying and monitoring patients suffering from the disease. Conventional radiography, while unable to visualize active inflammation, is the most valuable classical tool for identification of structural changes in AS 1 . The typical manifestations of bone formation in AS usually involve the axial skeleton, including spine, sacroiliac and hip joints, while ossification of the entheses may occur also peripherally.
The characteristic radiographic changes in AS, related to bone formation, include Computed tomography, superior to conventional radiography by depicting layer-by-layer changes, has additional value in disclosing bony growth particularly in locations where x-ray imaging is difficult, such as within sacroiliac joints or posterior spinal elements ( Figure 5 ). Magnetic resonance imaging, on the contrary, is more useful in demonstrating signs of active inflammation about joints, while changes related to bone formation may be missed due to the magnetic properties of calcium compounds within new bone.
Bone formation per se is not pathognomonic for AS, as it is also a feature of other spondyloarthropathies, as well as of osteoarthritis, diffuse idiopathic skeletal hyperostosis, alkaptonuria and other disorders. The pattern of bone formation in each of these diseases, however, is unique, allowing for proper differentiation in the majority of cases.
Of note, bone formation is not only a diagnostic feature of AS, but is also a measure of the pathologic progression of the disease. Standard quantitative assessment of this new bone formation, used in clinical trials and research of AS, is focused mainly on the cervical and lumbar segments of the spine. Four methods, developed to score structural changes in AS, include the Bath AS Radiology Index (BASRI), the Stoke AS Spinal Score (SASSS), modified SASSS (mSASSS) Competing interests: none declared. Conflict of interests: none declared.
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and Radiographic AS Spinal Score (RASSS). The last three methods are primarily based on scoring the presence of 'squaring' of vertebral bodies, characteristic sclerosis of bone, bony erosions and, particularly, syndesmophytes and bridging ankylosis along the spine, while the BASRI also scores sacroiliac joints and, in its modified form, hip joints (BASRIhip). mSASSS is currently considered the best method for scoring the radiographic progression of AS, while BASRI remains useful as an instrument for the staging of AS
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.
Pathogenesis of bone formation in AS
Histological data available from studies conducted on biopsies and/or autopsies of patients with AS suggest that an active inflammatory process, probably originating in the subchondral bone marrow, precedes new bone formation. As such, early sacroiliitis is characterized mainly by infiltration of the synovium, the cartilage and the bone with large number of macrophages, as well as lymphocytes and plasmacytes. Mild osteoblastic activity is already seen at the edges of bone trabeculae at this early stage. More advanced sacroiliitis manifests by osteoclastic resorption of the subchondral bone, the ongoing presence of a dense inflammatory infiltrate and appearance of abundant, loose extracellular matrix with many active osteoblasts seen. At a later stage, the sacroiliac joints are filled by granulation tissue: with islands of metaplastic cartilage, and fibroblasts, chondrocytes and chondroblasts, some of them hypertrophic and calcified, present; while osteoblasts synthesize endochondral bone around vascular buds 4 . This endochondral type of bone formation, with formation of cartilage skeleton which is eventually replaced by bone, has been also shown to be the leading mechanism of the formation of syndesmophytes in patients with AS
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. Evidence of membranous type of bone formation, with mesenchymal stem cells differentiating directly into osteoblasts, omitting the chondrocyte intermediate state, has also been seen occasionally in patients with AS.
Molecular pathways leading to bone formation in AS have not been elucidated sufficiently. Abnormally active signalling by wingless-type (wnt)-like and bone morphogenic protein (BMP)-mediated pathways have been recently suggested as All authors contributed to conception and design, manuscript preparation, read and approved the final manuscript.
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major contributors to disease-related ossification in AS. In the normal bone, BMPs are critical in the triggering of endochondrial bone formation in its early stages, and wnt-related proteins stimulate new bone formation by direct effect on osteoblasts.
Studies on animal models of arthritis have found that blocking of Dickkoppf-1 (Dkk-1), which is a natural inhibitor of wnt pathway, leads to the formation of osteophytes and ankylosis of sacroiliac joints in tumour necrosis factor-a (TNF-a) transgenic mouse model 6 . Similarly, higher levels of noggin, an inhibitor of BMP signalling, were protective against ankylosis in DBA/1 mice prone to ankylosing enthesopathy 7 . Additional clinical studies have found some evidence that Dkk-1 is dysfunctional in AS patients 8, 9 , while reports on correlation of serum levels of sclerostin, another inhibitor of wnt pathway, or various proteins of the BMP pathway, with radiographic damage in AS, have not been consistent [10] [11] [12] [13] . The conundrum of bone formation in AS is further complicated by the concurrence of local ossification resulting in the development of syndesmophytes and ankylosis, on the one hand, and generalized bone loss and osteoporosis, on the other hand, in the same patients (Figure 4) 14 . These simultaneous phenomena are considered by most authorities to be related, at least partially, to the inflammation of AS; thus, the speculation that osteoporosis may be related primarily to the systemic effects of inflammation while bony growth is a function of its local effects seems justified. In this context, the potential local effects of transforming growth factor-β1 (TGF-β1) on AS-related bone formation may be of interest. TGF-β1 was detected in sacroiliac biopsies in patients with advanced AS 15 , as well as in the synovial fluid of patients with spondyloarthritides in increased concentrations as compared with other rheumatic disorders 16 . The literature suggests that TGF-β1 is heavily involved in the pathogenesis of osteoarthritis 17 , osteophyte formation 18 and ossification of spinal ligaments 19 , supporting the hypothesis that TGF-β1 may be a central cytokine-regulating bone formation in a variety of conditions. Convincing evidence for the Competing interests: none declared. Conflict of interests: none declared.
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involvement of TGF-β1 in AS bone formation is, however, still lacking at this point.
The link between inflammation of AS and radiographic disease progression is not linear nor simple, however. While the above noted histological data, as well as experiments on the HLA-B27 transgenic animal models 20 , suggest that inflammation and bone formation are strongly coupled in AS, more recent data have demonstrated that new bone formation may progress independently of the inflammatory process, and may even be accelerated by the resolution of inflammation 21 . These observations have spawned the proposition of a hypothesis of a disconnect between inflammation and bone formation in AS. According to this hypothesis, some aetiologic trigger simultaneously induces inflammatory reaction and endochondral bone formation, but two of these pathways remain uncoupled during disease development 22 . MRI-based studies conducted on AS patients treated with anti-TNFa agents have suggested that early suppression of inflammation may prevent future bone formation, and yet a long-standing inflammatory process, even if eventually effectively treated, may proceed, independent of inflammation, to progressive bone formation 23 .
Clinical aspects of bone formation in AS
Radiographic damage in AS is associated with the impairment of spinal mobility and correlates long term with interference in functioning. The clinical measurements of spinal mobility, reflecting the structural damage in AS patients, are of particular significance in the later stages of the disease, while in the earlier disease, spinal mobility may be more influenced by the reversible inflammatory process
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. The pattern of spinal damage in AS is unpredictable, with the possibility of cervical, thoracic or lumbar involvement dominant in different persons. Thus, clinical evaluation of spinal mobility in these patients should cover all spinal segments. The measurements of tragus-to-wall, occiput-to-wall distances and cervical rotation can be used for determining limitations of cervical spine mobility; chest expansion measurement allows to detect limitations in movement of thoracic spine/costovertebral joints, while fingers-to-floor distance, lumbar flexion (Schober test) and lateral lumbar flexion can assess restriction in lumbar spine motion. Maximal inter-malleolar distance is used for the assessment of hip joint involvement.
Of relevance, the rate of new bone formation differs among individuals and is rather slow, with an estimated follow-up duration of at least 2 years necessary to show measurable progression in clinical studies 25 . Some of the patients with AS will not develop spinal syndesmophytes at all during the disease course. A recent study on 132 patients with established AS showed that only 60% of patients had syndesmophytes at the baseline, and about 50% developed new syndesmophytes during a 4-year period of follow-up. Of importance, only the presence of existing syndesmophytes was a significant predictor of new bone formation in this study
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. Similarly, in other studies performed on patients with AS or axial spondyloarthritis, the presence of pre-existing syndesmophytes has always been found to be the most powerful predictor of future structural damage. Elevated CRP and smoking also seem to drive new syndesmophyte growth in AS patients 27 . Worthy of note, bone formation occurs faster in males with AS as compared with females. The localization of new syndesmophyte growth may also differ between genders, with females developing more cervical, and males developing predominantly lumbar, syndesmophytes 28 .
The negative long-term consequences of bone formation in AS patients reflected in radiographic damage make this an important target for therapeutic intervention. Anti-TNF-a agents, widely used nowadays in the treatment of AS, while highly effective in the alleviation of clinical, laboratory and imaging signs of the inflammatory process related to AS, have failed to prevent or slow the radiographic damage in a series of trials. The only medicines, shown currently to delay the process of bone formation in AS patients, are nonsteroidal anti-inflammatory drugs (NSAIDs), medications traditionally used in AS for many decades. Two studies have demonstrated the dose-dependent efficacy of NSAIDs in slowing syndesmophyte growth in AS patients, purportedly through their anti-prostaglandin action 29, 30 . Physical therapy and intense exercising, while never examined for their propensity to influence the rate of new bone formation in AS, can improve spinal mobility and functional status of patients, thus diminishing the negative clinical consequences of structural damage related to bone formation in AS 31 . Thus, management combining both pharmacological and nonpharmacological approaches to deal with the long-term consequences of AS should be advocated for all patients diagnosed with the disease.
Discussion
Beyond amelioration of signs and symptoms of arthritis, disease course modification has become a goal in modern rheumatology in the last decade. The recognized ability of the biologic agents to virtually shut down the process of erosion formation in rheumatoid arthritis (RA) has revolutionized the approach to the management of RA patients, fundamentally changed the outcomes of their treatment and led to the anticipation that a similar approach will result in disease modification of other rheumatic disorders, primarily AS. The expectation that new bone formation in AS patients will be inhibited by anti-TNF-a medicines, founded on the superb clinical efficacy of these medicines with respect to pain and stiffness control, was not confirmed in several 2-year long clinical trials. The failure of these biologics to slow radiographic progression of AS has, however, triggered new intense basic research in the field of AS-related bone formation. It has also put to question our ability to recognize, calculate and evaluate the significance of this bone formation in both clinical trials and individual patients. While the recognition of new AS-related ossification is still primarily based on traditional radiography, new more sensitive scoring systems, such as mSASSS, have been proposed; and experience in clinical research, learning both the natural history of AS progression and ways to intervene in it, has been gained. Finally, the discoveries in the field gained by basic research open new horizons and inspire hope for ferreting out the mystery of AS-related bone formation in the near future.
Conclusion
Bone formation is a hallmark pathological feature of AS and the primary cause of long-term disability in these patients. Radiographic features of bone formation in AS are well known, and conventional radiography represents a convenient tool for the measurement of disease progression. The pathogenesis of bone formation, as well as its relation to the inflammatory process, is poorly understood, but the disease-related breakdown in pathways regulating bone remodelling may play a role. As the rates and severity of bone formation vary significantly among AS patients, biomarkers for bone formation and prediction of structural damage would help to improve and individualize management of patients suffering from AS.
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